Commited to health for 70 years

Novartis continues its investments in Lek, a Sandoz company. To date, Novartis invested more than 1.7 billion Euros, half of which was invested in the development and the other half in modernization and expansion of production capabilities.

Read key business and development news in our company and various activities that we support and co-create. You can also browse the news archives dating back to 1998, our photo library and visual identity. For additional information, you can write to us at info.lek@sandoz.com.

Press releases
20. 9. 2017

Novartis announced that the European Commission (EC) approved Kisqali® (ribociclib) in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive, human ...

30. 8. 2017

Lek maintained their high dynamic regarding investments. Novartis earmarked almost EUR 170 million for Slovenia, bringing the total to EUR 1.9 billion over the last ...

21. 8. 2017

Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains ...

25. 7. 2017

Sandoz today announces the expansion of a pilot project with leading charity World Child Cancer, aimed at improving access to treatment and optimizing survival outcomes ...

Contact

Lek d.d.
Verovškova 57, 1526 Ljubljana, Slovenia
T: +386 1 580 21 11
F: +386 1 568 35 17
info.lek@sandoz.com
VAT No.: SI87916452
Registration number: 1732811000
Nominal capital: 48.402.003,00 EUR

Ask us

Katarina Klemenc
T: +386 1 580 22 43
F: +386 1 580 24 32
info.lek@sandoz.com